Product Pipeline

•  Zerenex^TM 
   
  •  About Zerenex^TM 
  •  Market Opportunity 
  •  Development Status 
  •  Clinical Trials 
    - Phase II Dose Ranging Study 
    



•  KRX-0401 (Perifosine) 
   
  •  About KRX-0401 (Perifosine) 
  •  Pre-Clinical Data 
  •  Development Status 
  •  Clinical Trials 
    

Zerenex (ferric citrate) is an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S. Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and the Phase 3 clinical program of Zerenex is ongoing under an SPA agreement with the FDA. Zerenex has also completed Phase 2 development in Japan by our Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

Copyright © 2010 by Keryx Biopharmaceuticals, Inc. Update Notice | Disclaimer | Contact Us

Disclaimer: This investigational drug product has not been approved by the US Food and Drug Administration for safety and effectiveness. This investigational drug product is still undergoing clinical study to verify its safety and effectiveness